N

NovoCure Limited
D

NVCR

16.690
USD
-0.09
(-0.54%)
مغلق
حجم التداول
48,102
الربح لكل سهم
-2
العائد الربحي
-
P/E
-11
حجم السوق
1,860,695,231
أصول ذات صلة
BAX
BAX
0.200
(0.67%)
30.000 USD
C
CYH
0.01000
(0.30%)
3.31500 USD
E
EHC
-0.590
(-0.49%)
119.160 USD
HCA
HCA
0.40
(0.11%)
377.30 USD
H
HSTM
-0.820
(-2.99%)
26.600 USD
I
INGN
0.04000
(0.61%)
6.64000 USD
S
SEM
-0.095
(-0.64%)
14.845 USD
U
UHS
0.508
(0.30%)
171.718 USD
المزيد
الأخبار المقالات

العنوان: NovoCure Limited

القطاع: Healthcare
الصناعة: Medical Devices
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.